Sunitinib: Difference between revisions

Line 15:

{| class="wikitable" border="1" width="50%" style="text-align:center"

|-

! colspan="6" align="center"| VEGFR Inhibitor [[~~Pharmaceutical_Drugs#Pharmacokinetics_Translated|~~Pharmacokinetics]]<ref>D. Smith et al. Br J Clin Pharmacol. 2009 April; 67(4): 421–426.</ref><ref>R. Khosravan, et al. General Poster Session, Developmental Therapeutics: Cytotoxic Chemotherapy, J Clin Oncol 26: 2008 (May 20 suppl; abstr 2578)</ref><ref>PMID:16133532</ref><ref>PMID:20821331</ref><ref>PMID:20717111</ref>

! colspan="6" align="center"| VEGFR Inhibitor [[Pharmacokinetics]]<ref>D. Smith et al. Br J Clin Pharmacol. 2009 April; 67(4): 421–426.</ref><ref>R. Khosravan, et al. General Poster Session, Developmental Therapeutics: Cytotoxic Chemotherapy, J Clin Oncol 26: 2008 (May 20 suppl; abstr 2578)</ref><ref>PMID:16133532</ref><ref>PMID:20821331</ref><ref>PMID:20717111</ref>

|-

! Parameter

Line 21:

! [[Sorafenib]] (Nexavar)

|-

! [[~~Pharmaceutical_Drugs~~#Tmax|Tmax]] (hr)

! [[Pharmacokinetics#Tmax|Tmax]] (hr)

! 8

! 8.3

|-

! [[~~Pharmaceutical_Drugs~~#Cmax|Cmax]] (ng/ml)

! [[Pharmacokinetics#Cmax|Cmax]] (ng/ml)

! 24.6

! 460

|-

! [[~~Pharmaceutical_Drugs~~#Bioavailability_.28F.29|Bioavailability]] (%)

! [[Pharmacokinetics#Bioavailability_.28F.29|Bioavailability]] (%)

! Variable

! 29-49

|-

! [[~~Pharmaceutical_Drugs~~#Protein_Binding|Protein Binding]] (%)

! [[Pharmacokinetics#Protein_Binding|Protein Binding]] (%)

! 95

! 99

|-

! [[~~Pharmaceutical_Drugs~~#Half_Life_.28T1.2F2.29|T1/2]] (hr)

! [[Pharmacokinetics#Half_Life_.28T1.2F2.29|T1/2]] (hr)

! 83

! 29

|-

! [[~~Pharmaceutical_Drugs~~#Area_Under_the_Curve_.28AUC.29|AUC]] (ng/ml/hr)

! [[Pharmacokinetics#Area_Under_the_Curve_.28AUC.29|AUC]] (ng/ml/hr)

! 1921

! 11040

Sunitinib: Difference between revisions

Navigation menu

Page actions

Page actions

Personal tools

Navigation

Search

Tools

@@ Line 15: / Line 15: @@
 {| class="wikitable" border="1" width="50%" style="text-align:center"
 |-
-!  colspan="6" align="center"| VEGFR Inhibitor [[Pharmaceutical_Drugs#Pharmacokinetics_Translated|Pharmacokinetics]]<ref>D. Smith et al. Br J Clin Pharmacol. 2009 April; 67(4): 421–426.</ref><ref>R. Khosravan, et al. General Poster Session, Developmental Therapeutics: Cytotoxic Chemotherapy, J Clin Oncol 26: 2008 (May 20 suppl; abstr 2578)</ref><ref>PMID:16133532</ref><ref>PMID:20821331</ref><ref>PMID:20717111</ref>
+!  colspan="6" align="center"| VEGFR Inhibitor [[Pharmacokinetics]]<ref>D. Smith et al. Br J Clin Pharmacol. 2009 April; 67(4): 421–426.</ref><ref>R. Khosravan, et al. General Poster Session, Developmental Therapeutics: Cytotoxic Chemotherapy, J Clin Oncol 26: 2008 (May 20 suppl; abstr 2578)</ref><ref>PMID:16133532</ref><ref>PMID:20821331</ref><ref>PMID:20717111</ref>
 |-
 ! Parameter
@@ Line 21: / Line 21: @@
 ! [[Sorafenib]] (Nexavar)
 |-
-! [[Pharmaceutical_Drugs#Tmax|T<sub>max</sub>]] (hr)
+! [[Pharmacokinetics#Tmax|T<sub>max</sub>]] (hr)
 ! 8
 ! 8.3
 |-
-! [[Pharmaceutical_Drugs#Cmax|C<sub>max</sub>]] (ng/ml)
+! [[Pharmacokinetics#Cmax|C<sub>max</sub>]] (ng/ml)
 ! 24.6
 ! 460
 |-
-! [[Pharmaceutical_Drugs#Bioavailability_.28F.29|Bioavailability]] (%)
+! [[Pharmacokinetics#Bioavailability_.28F.29|Bioavailability]] (%)
 ! Variable
 ! 29-49
 |-
-! [[Pharmaceutical_Drugs#Protein_Binding|Protein Binding]] (%)
+! [[Pharmacokinetics#Protein_Binding|Protein Binding]] (%)
 ! 95
 ! 99
 |-
-! [[Pharmaceutical_Drugs#Half_Life_.28T1.2F2.29|T<sub>1/2</sub>]] (hr)
+! [[Pharmacokinetics#Half_Life_.28T1.2F2.29|T<sub>1/2</sub>]] (hr)
 ! 83
 ! 29
 |-
-! [[Pharmaceutical_Drugs#Area_Under_the_Curve_.28AUC.29|AUC]] (ng/ml/hr)
+! [[Pharmacokinetics#Area_Under_the_Curve_.28AUC.29|AUC]] (ng/ml/hr)
 ! 1921
 ! 11040